Oki, Toshihiko
Mercier, Francois
Kato, Hiroki
Jung, Yookyung http://orcid.org/0000-0003-2790-6016
McDonald, Thomas O.
Spencer, Joel A.
Mazzola, Michael C.
van Gastel, Nick http://orcid.org/0000-0002-0563-3590
Lin, Charles P.
Michor, Franziska http://orcid.org/0000-0003-4869-8842
Kitamura, Toshio http://orcid.org/0000-0001-7855-1767
Scadden, David T. http://orcid.org/0000-0001-9821-7133
Article History
Received: 16 December 2019
Accepted: 1 December 2020
First Online: 11 January 2021
Competing interests
: D.T.S. is a director and equity holder of Agios Pharmaceuticals, Magenta Therapeutics, Editas Medicines, Clear Creek Bio, and LifeVaultBio; he is a founder of Fate Therapeutics and Magenta Therapeutics and a consultant to FOG Pharma, VcanBio, and Flagship Pioneering. T.O. is currently a full-time employee of Takeda Pharmaceuticals Inc. Co. The remaining authors declare no competing interests.